by Tim Olmstead | Jan 12, 2022 | Uncategorized
Insights Our Blog Scott Patton Spotlight At Alinea Group, Scott provides ongoing support, data analytics, pharmacy billing and charge capture. He also works to bring consulting support to various hospital systems through his expertise as an EMR and pharmacy systems...
by Tim Olmstead | Dec 21, 2021 | Uncategorized
Insights Our Blog The Crossroads of 340B and Biosimilars: Challenges and Opportunities If you are a hospital or pharmacy provider, it’s no surprise that the growth of biologic drug spending (14.6%) was more than double the growth of overall drug spending (6.1%)...
by Tim Olmstead | Dec 3, 2021 | Uncategorized
Insights Our Blog Jamila Seibel Spotlight Meet Jamila! She has a strong understanding of the medication use process as it relates to pharmacy operations, 340B integration, patient care, and healthcare outcomes. We’re thankful to have her on our team! How long...
by Tim Olmstead | Aug 6, 2021 | Uncategorized
Insights Our Blog A Level Best Compliance Approach to 340B Optimization Since its introduction in 1992, the 340B Program has vastly altered the pharmacy landscape. In these very uncertain times, as we continue to grasp COVID-19’s longevity and struggle to predict a...
by Tim Olmstead | Apr 1, 2021 | Uncategorized
Insights Our Blog The Future of 340B: An Alinea Expert’s Perspective An Interview with Keith Chop | April 1, 2021 The past year has been one unlike any other. As facilities are navigating new territories, it’s important to stay on top of all statuses and...
